Phase 2a clinical trial for ulcerative colitis using adrenomedullin

Effects of adrenomedullin in steroid-resistant patients with ulcerative colitis: randomized, double-blind, placebo-controlled phase 2a clinical trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080225159

Enrollment

Registered

2020-04-10

Start date

2017-03-29

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ulcerative colitis

Interventions

investigational material(s) Generic name etc : adrenomedullin INN of investigational material : adrenomedullin Therapeutic category code : 249 Other hormone preparations (including antihormone prepara

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with steroid-resistant ulcerative colitis

Exclusion criteria

Exclusion criteria: Patient using biologics Patient with fulminant ulcerative colitis (UC) Patient need early operation for UC Patient with precancerous lesion(s) in the colon Patient with active infection Patient with severe complication(s) Patient with malignancy or past history of malignancy Pregnant woman

Design outcomes

Primary

Measure	Time frame
efficacy change of Mayo scores at week 2	—

Secondary

Measure	Time frame
safety efficacy change of Mayo scores at week 8 effective rate of Mayo scores improvement of Mayo scores Lichtiger index Mayo endoscopy sub-score (MES) fecal immunochemical test and calprotectin at week 2 dose of steroid	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026